Atossa Therapeutics' Q3 Loss Widens Amid Soaring R&D Costs

TL;DR

**ATOS is burning cash faster, but it's a necessary evil for a biotech with a pipeline; watch for clinical trial milestones, not quarterly profits.**

AI Summary

ATOSSA THERAPEUTICS, INC. reported a net loss of $8.692 million for the three months ended September 30, 2025, an increase from a net loss of $7.230 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $23.833 million, up from $19.157 million in the prior year. Research and development expenses significantly increased to $15.029 million for the nine months ended September 30, 2025, compared to $10.714 million in 2024, reflecting increased clinical trial activities. General and administrative expenses also rose to $10.676 million from $9.756 million year-over-year. The company's cash and cash equivalents decreased to $51.845 million as of September 30, 2025, from $71.084 million at December 31, 2024, with $19.223 million used in operating activities during the nine-month period. Despite these losses, management believes its current cash will finance operations for at least one year. The strategic outlook involves continued funding through equity offerings, debt, or collaborations to support its oncology drug development, particularly in breast cancer.

Why It Matters

Atossa's widening net loss and increased R&D spending signal aggressive investment in its oncology pipeline, primarily breast cancer therapeutics. For investors, this indicates a high-risk, high-reward profile, as success in clinical trials could lead to substantial returns, while failures could deplete capital. Employees are likely to see continued focus on drug development, potentially leading to growth in R&D roles. Customers, specifically future patients, depend on the successful and timely development of these innovative medicines. In the competitive biotech landscape, Atossa's ability to secure additional funding and advance its drug candidates will be crucial for its long-term viability and market position.

Risk Assessment

Risk Level: high — The company reported a net loss of $23.833 million for the nine months ended September 30, 2025, and used $19.223 million in operating activities. Cash and cash equivalents decreased from $71.084 million to $51.845 million, indicating a significant cash burn rate without an established revenue source, posing a substantial liquidity risk.

Analyst Insight

Investors should closely monitor ATOS's clinical trial progress and upcoming funding announcements. Given the high R&D spend and lack of revenue, new capital raises are highly probable, which could dilute existing shareholders. Consider this a speculative investment based on future drug development success.

Financial Highlights

net Income

-$23.833M

cash Position

$51.845M

Key Numbers

• $23.833M — Net Loss (9 months) (Increased from $19.157M in prior year, indicating higher operating expenses.)
• $15.029M — Research and Development Expenses (9 months) (Increased by 40.27% from $10.714M, reflecting intensified drug development.)
• $51.845M — Cash and Cash Equivalents (Decreased from $71.084M at Dec 31, 2024, showing significant cash burn.)
• $19.223M — Net Cash Used in Operating Activities (9 months) (Increased from $13.979M, highlighting accelerated cash consumption.)
• 129,171,424 — Common Stock Shares Outstanding (As of November 1, 2025, indicating potential for future dilution.)

Key Players & Entities

• ATOSSA THERAPEUTICS, INC. (company) — Registrant
• Nasdaq Capital Market (regulator) — Exchange where Common Stock is registered
• $8.692 million (dollar_amount) — Net loss for Q3 2025
• $7.230 million (dollar_amount) — Net loss for Q3 2024
• $23.833 million (dollar_amount) — Net loss for nine months ended Sept 30, 2025
• $19.157 million (dollar_amount) — Net loss for nine months ended Sept 30, 2024
• $15.029 million (dollar_amount) — R&D expenses for nine months ended Sept 30, 2025
• $10.714 million (dollar_amount) — R&D expenses for nine months ended Sept 30, 2024
• $51.845 million (dollar_amount) — Cash and cash equivalents as of Sept 30, 2025
• $19.223 million (dollar_amount) — Net cash used in operating activities for nine months ended Sept 30, 2025

FAQ

Risk Factors

• Significant Cash Burn and Need for Future Financing [high — financial]: The company's cash and cash equivalents decreased to $51.845 million as of September 30, 2025, from $71.084 million at December 31, 2024. Net cash used in operating activities was $19.223 million for the nine months ended September 30, 2025. Management believes current cash will finance operations for at least one year, but future operations will likely require additional funding through equity offerings, debt, or collaborations.
• Increasing Net Losses [high — financial]: Atossa Therapeutics reported a net loss of $8.692 million for the three months ended September 30, 2025, an increase from $7.230 million in the prior year. The nine-month net loss was $23.833 million, up from $19.157 million in the prior year. This trend indicates rising operational costs outpacing revenue generation.
• High Research and Development Expenses [medium — operational]: Research and development expenses significantly increased to $15.029 million for the nine months ended September 30, 2025, compared to $10.714 million in the same period of 2024, a 40.27% increase. While necessary for drug development, these high costs contribute to the company's net losses.
• Rising General and Administrative Expenses [medium — operational]: General and administrative expenses rose to $10.676 million for the nine months ended September 30, 2025, from $9.756 million in the prior year. This increase, while less dramatic than R&D, adds to the overall operating cost burden.
• Potential for Shareholder Dilution [medium — financial]: The company had 129,171,424 common stock shares outstanding as of November 1, 2025. Given the need for future financing, there is a significant risk of further equity offerings, which could dilute the ownership stake of existing shareholders.
• Drug Development and Regulatory Approval Risks [high — regulatory]: The company's core business relies on the successful development and regulatory approval of oncology drugs. Clinical trial failures, delays, or inability to secure FDA approval represent significant risks to the company's future revenue and viability.

Industry Context

The oncology drug development sector is highly competitive and capital-intensive, characterized by long development cycles and high failure rates. Companies like Atossa Therapeutics operate in a landscape where significant investment in R&D is necessary to bring novel therapies to market. Success is heavily dependent on clinical trial outcomes and navigating complex regulatory pathways.

Regulatory Implications

Atossa Therapeutics faces significant regulatory hurdles inherent in drug development. The company must successfully navigate clinical trials and gain approval from regulatory bodies like the FDA. Any setbacks in the regulatory process, such as trial failures or delays, can severely impact the company's financial health and future prospects.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress closely for signs of efficacy and potential regulatory milestones.
2. Evaluate the company's cash burn rate and its ability to secure future financing to avoid dilution or operational disruption.
3. Assess the competitive landscape and the company's differentiation in its target therapeutic areas, particularly breast cancer.
4. Consider the potential for future equity offerings and their dilutive impact on existing shareholdings.

Glossary

Net Loss

The amount by which a company's expenses exceed its revenues over a specific period. (Indicates the company is currently unprofitable, with losses increasing year-over-year.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Represents a significant and growing investment for Atossa, crucial for its drug pipeline but also a major driver of losses.)

Cash and Cash Equivalents

Highly liquid financial instruments with original maturities of three months or less. (Represents the company's readily available funds to meet short-term obligations and operational needs.)

Net Cash Used in Operating Activities

The net amount of cash used by a company's normal business operations during a period. (Shows the rate at which the company is consuming cash from its core business, which is increasing.)

Common Stock Shares Outstanding

The total number of shares of common stock that have been issued and are held by investors. (A key metric for understanding potential shareholder dilution, especially if the company needs to issue more stock for financing.)

Year-Over-Year Comparison

The latest 10-Q filing shows a continued trend of increasing net losses, with a 21.5% rise in the nine-month net loss compared to the prior year, driven by a substantial 40.27% increase in R&D expenses. Cash reserves have also declined, indicating a higher cash burn rate. While G&A expenses have also risen, the primary driver of increased costs is the intensified investment in drug development activities.

Key Financial Figures

• $0.18 — nge on which registered Common Stock, $0.18 par value ATOS The Nasdaq Capital M

Filing Documents

• atos-20250930.htm (10-Q) — 1815KB
• atos-ex31_1.htm (EX-31.1) — 14KB
• atos-ex31_2.htm (EX-31.2) — 14KB
• atos-ex32_1.htm (EX-32.1) — 9KB
• atos-ex32_2.htm (EX-32.2) — 10KB
• img97318493_0.jpg (GRAPHIC) — 237KB
• 0001193125-25-276160.txt ( ) — 6456KB
• atos-20250930.xsd (EX-101.SCH) — 752KB
• atos-20250930_htm.xml (XML) — 808KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24 PART II. OTHER INFORMATION 25 Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 3. Defaults Upon Senior Securities 46 Item 4. Mine Safety Disclosures 46 Item 5. Other Information 46 Item 6. Exhibits 47

—FINA NCIAL INFORMATION

PART I—FINA NCIAL INFORMATION

CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS - UNAUDITED

ITEM 1. CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS - UNAUDITED ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED B ALANCE SHEETS (amounts in thousands, except share and per share data) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 51,845 $ 71,084 Restricted cash 110 110 Prepaid materials 3,143 2,098 Prepaid expenses and other current assets 580 1,165 Total current assets 55,678 74,457 Other assets 2,334 1,987 Total assets $ 58,012 $ 76,444 Liabilities and stockholders' equity Current liabilities Accounts payable $ 3,536 $ 679 Accrued expenses 1,989 919 Payroll liabilities 1,125 1,862 Other current liabilities 1,575 1,507 Total current liabilities 8,225 4,967 Total liabilities 8,225 4,967 Commitments and contingencies (Note 13) — — Stockholders' equity Convertible preferred stock - $ 0.001 par value; 10,000,000 shares authorized; 577 and 582 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Common stock - $ 0.18 par value; 350,000,000 shares authorized; 129,171,424 and 129,170,004 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 23,488 23,488 Additional paid-in capital 263,399 261,256 Treasury stock, at cost; 1,320,046 shares of common stock at September 30, 2025 and December 31, 2024 ( 1,475 ) ( 1,475 ) Accumulated deficit ( 235,625 ) ( 211,792 ) Total stockholders' equity 49,787 71,477 Total liabilities and stockholders' equity $ 58,012 $ 76,444 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 3 ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STAT EMENTS OF OPERATIONS (amounts in thousands, except share and per share data) (Unaudited) For the Three Months Ended September 30, For the Nine

View Full Filing

View this 10-Q filing on SEC EDGAR